Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

6.620 -0.430 (-6.10%)
Official Closing Price Updated: 8:00 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
39 40 Next >
Cybin to Participate in PSYCH Symposium London 2023
From Cybin Inc.
Via Business Wire
Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer
From Cybin Inc.
Via Business Wire
Cybin's FY2023 Financials, Guidance And Appointment Of Sanford R. Climan As Strategic Advisor
Psychedelics biopharma company Cybin Inc. (NYSE: CYBN) shared its financial results for the fiscal year ended this March 31 as well as recent business highlights. Numbers show: Total cash of $12.5... 
Via Benzinga
Cybin: Q4 Earnings Insights
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases FY 2023 Financial Report, Business Highlights
Via Investor Brand Network
Exposures Product Safety
Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Names Seasoned Veteran as Strategic Advisor
Via Investor Brand Network
Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Participate at Psychedelic Science 2023 Conference
Via Investor Brand Network
Cybin to Participate in the 2023 MAPS Psychedelic Science Conference
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Participate at Upcoming H.C. Wainwright Neuropsychiatry Conference
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Report on Status of Capital, Product Development
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Inc. Provides Corporate Update
From Cybin Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 69 stocks hit new 52-week lows. 
Via Benzinga
Psyched: Millions From Institutional Investor And Fed Funding For Research, M&As, Women Veterans And More
Major Investor Commits $30 Million To Psychedelics Funding 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Changes in Scientific Management Team
Via Investor Brand Network
Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones
From Cybin Inc.
Via Business Wire
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances
Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May. 
Via Talk Markets
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Jefferies Healthcare Conference
Via Investor Brand Network
Cybin to Present at the Jefferies Healthcare Conference
From Cybin Inc.
Via Business Wire
Major Investor Commits $30M To Psychedelics Funding
Canadian psychedelics biotech Cybin Inc. (NYSE: CYBN) entered into a common share purchase agreement with institutional investor Lincoln Park Capital Fund (LPC) for the sale of up to $30... 
Via Benzinga
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics... 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Common Stock Purchase Agreement Totaling $30M
Via Investor Brand Network
Topics Derivatives
Exposures Derivatives
Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund
From Cybin Inc.
Via Business Wire
Novel DMT Compound For Anxiety Shows Clinical Progress: Robust Effects Within 2 Minutes
Canadian clinical-stage psychedelics company Cybin Inc. (NYSE: CYBN) announced that the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing 
Via Benzinga
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Initiates Dosing of First Participants in Phase 1 Clinical Trial
Via Investor Brand Network
Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
From Cybin Inc.
Via Business Wire
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
Via Benzinga
Trial On DMT Drug For Anxiety And Depression Ends Participant Dosing, Study Results Soon Released
Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug... 
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Doses Last Subject in Phase 1, Part B CYB004-E Trial
Via Investor Brand Network
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.